Literature DB >> 17600119

Monoclonal antibody-mediated CD200 receptor signaling suppresses macrophage activation and tissue damage in experimental autoimmune uveoretinitis.

David A Copland1, Claudia J Calder, Ben J E Raveney, Lindsay B Nicholson, Joseph Phillips, Holly Cherwinski, Maria Jenmalm, Jonathon D Sedgwick, Andrew D Dick.   

Abstract

Macrophage responses are regulated by multiple secreted factors as well as by cell surface receptors, including the inhibitory signals resulting from ligation of myeloid CD200 receptors (CD200R) by the widely distributed CD200. In the absence of CD200, animals display increased susceptibility to autoimmunity and earlier onset aggressive autoimmune disease. In these current experiments, an agonist monoclonal rat anti-mouse CD200R (DX109) antibody delivered a negative signal to bone marrow-derived macrophages, which suppressed interferon (IFN)gamma-mediated nitric oxide (NO) and interleukin-6 production. Experimental autoimmune uveoretinitis (EAU) was used as a model of organ-specific autoimmunity in the eye, a tissue with extensive neuronal and endothelial CD200 expression. In mice lacking CD200 (CD200(-/-)), increased numbers of retina-infiltrating macrophages displaying heightened NO responses were observed during EAU. In addition, we aimed to suppress disease by maintaining tonic suppression of macrophage activation via CD200R. Systemically administered DX109 monoclonal antibody suppressed EAU despite maintained T-cell proliferation and IFNgamma production. Furthermore, locally administered DX109 monoclonal antibody resulted in an earlier resolution of disease. These experiments demonstrate that promoting CD200R-mediated signaling can successfully prevent full expression of IFNgamma-mediated macrophage activation and protect against tissue damage during autoimmune responses.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17600119      PMCID: PMC1934542          DOI: 10.2353/ajpath.2007.070272

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  27 in total

1.  Putting the brakes on innate immunity: a regulatory role for CD200?

Authors:  C Nathan; W A Muller
Journal:  Nat Immunol       Date:  2001-01       Impact factor: 25.606

2.  Down-regulation of the macrophage lineage through interaction with OX2 (CD200).

Authors:  R M Hoek; S R Ruuls; C A Murphy; G J Wright; R Goddard; S M Zurawski; B Blom; M E Homola; W J Streit; M H Brown; A N Barclay; J D Sedgwick
Journal:  Science       Date:  2000-12-01       Impact factor: 47.728

3.  Identification of a new epitope of human IRBP that induces autoimmune uveoretinitis in mice of the H-2b haplotype.

Authors:  D Avichezer; P B Silver; C C Chan; B Wiggert; R R Caspi
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-01       Impact factor: 4.799

4.  Transplant tolerance modifying antibody to CD200 receptor, but not CD200, alters cytokine production profile from stimulated macrophages.

Authors:  R M Gorczynski
Journal:  Eur J Immunol       Date:  2001-08       Impact factor: 5.532

5.  CD200 immunoadhesin suppresses collagen-induced arthritis in mice.

Authors:  R M Gorczynski; Z Chen; K Yu; J Hu
Journal:  Clin Immunol       Date:  2001-12       Impact factor: 3.969

6.  Distribution of OX2 antigen and OX2 receptor within retina.

Authors:  A D Dick; C Broderick; J V Forrester; G J Wright
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-01       Impact factor: 4.799

7.  Lymphoid/neuronal cell surface OX2 glycoprotein recognizes a novel receptor on macrophages implicated in the control of their function.

Authors:  G J Wright; M J Puklavec; A C Willis; R M Hoek; J D Sedgwick; M H Brown; A N Barclay
Journal:  Immunity       Date:  2000-08       Impact factor: 31.745

Review 8.  CD200 and membrane protein interactions in the control of myeloid cells.

Authors:  A Neil Barclay; Gavin J Wright; Gary Brooke; Marion H Brown
Journal:  Trends Immunol       Date:  2002-06       Impact factor: 16.687

9.  Retinal microenvironment controls resident and infiltrating macrophage function during uveoretinitis.

Authors:  Morag J Robertson; Lars P Erwig; Janet Liversidge; John V Forrester; Andrew J Rees; Andrew D Dick
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-07       Impact factor: 4.799

10.  Interphotoreceptor retinoid binding protein peptide-induced uveitis in B10.RIII mice: characterization of disease parameters and immunomodulation.

Authors:  D J Hankey; S L Lightman; D Baker
Journal:  Exp Eye Res       Date:  2001-03       Impact factor: 3.467

View more
  58 in total

Review 1.  Interplay between innate and adaptive immunity in the development of non-infectious uveitis.

Authors:  François Willermain; James T Rosenbaum; Bahram Bodaghi; Holly L Rosenzweig; Sarah Childers; Travis Behrend; Gerhild Wildner; Andrew D Dick
Journal:  Prog Retin Eye Res       Date:  2011-11-22       Impact factor: 21.198

2.  The immunosuppressive surface ligand CD200 augments the metastatic capacity of squamous cell carcinoma.

Authors:  Magda Stumpfova; Desirée Ratner; Edward B Desciak; Yehuda D Eliezri; David M Owens
Journal:  Cancer Res       Date:  2010-03-23       Impact factor: 12.701

3.  Tickling the CD200 receptor: A remedy for those irritating macrophages.

Authors:  Ralph Feuer
Journal:  Am J Pathol       Date:  2007-06-28       Impact factor: 4.307

Review 4.  Doyne lecture 2016: intraocular health and the many faces of inflammation.

Authors:  A D Dick
Journal:  Eye (Lond)       Date:  2016-09-16       Impact factor: 3.775

Review 5.  Neurobiology of microglial action in CNS injuries: receptor-mediated signaling mechanisms and functional roles.

Authors:  Xiaoming Hu; Anthony K F Liou; Rehana K Leak; Mingyue Xu; Chengrui An; Jun Suenaga; Yejie Shi; Yanqin Gao; Ping Zheng; Jun Chen
Journal:  Prog Neurobiol       Date:  2014-06-09       Impact factor: 11.685

Review 6.  Autoimmune uveitis: clinical, pathogenetic, and therapeutic features.

Authors:  Marcella Prete; Rosanna Dammacco; Maria Celeste Fatone; Vito Racanelli
Journal:  Clin Exp Med       Date:  2015-03-28       Impact factor: 3.984

7.  Tumor-derived vaccines containing CD200 inhibit immune activation: implications for immunotherapy.

Authors:  Zhengming Xiong; Elisabet Ampudia-Mesias; Rob Shaver; Craig M Horbinski; Christopher L Moertel; Michael R Olin
Journal:  Immunotherapy       Date:  2016-09       Impact factor: 4.196

8.  Systemic and local anti-C5 therapy reduces the disease severity in experimental autoimmune uveoretinitis.

Authors:  D A Copland; K Hussain; S Baalasubramanian; T R Hughes; B P Morgan; H Xu; A D Dick; L B Nicholson
Journal:  Clin Exp Immunol       Date:  2009-12-04       Impact factor: 4.330

9.  CD200Fc reduces TLR4-mediated inflammatory responses in LPS-induced rat primary microglial cells via inhibition of the NF-κB pathway.

Authors:  Li Jiang; Fan Xu; Wenjing He; Lifei Chen; Haibin Zhong; Yu Wu; Siming Zeng; Li Li; Min Li
Journal:  Inflamm Res       Date:  2016-03-08       Impact factor: 4.575

10.  Understanding the neurobiology of CD200 and the CD200 receptor: a therapeutic target for controlling inflammation in human brains?

Authors:  Douglas G Walker; Lih-Fen Lue
Journal:  Future Neurol       Date:  2013-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.